DifGen Pharmaceuticals

Meet the DifGen Pharmaceuticals Team at DCAT Week 2025! We’re excited to be attending DCAT 2025 in New York City from March 17-20! Our team is ready to connect, collaborate, and discuss innovative solutions shaping the future of pharmaceuticals. We’re looking forward to productive conversations, new partnerships, and strengthening existing relationships. Let’s make this DCAT Week one to remember! Reach out to schedule a meeting – we’d love to connect. #DCATWeek2025 #MeetTheTeam #DifGenPharmaceuticals #PharmaInnovation #Networking #HealthcareSolutions

DifGen Pharmaceuticals is thrilled to announce that we will be attending DCAT Week 2025 in New York City from March 17-20! Join us at The Benjamin Royal Sonesta (Suite 809 & 810) as we connect with industry leaders, explore new opportunities, and discuss innovative solutions in pharmaceutical development. We’re excited to meet our partners, clients, and peers — let’s collaborate and make a difference in healthcare together! 📍 Location: 125 East 50th Street, NY, NY 10022 📅 Dates: March 17-20, 2025 Reach out to schedule a meeting – we look forward to seeing you there! #DCATWeek2025 #DifGenPharmaceuticals #PharmaInnovation #Networking #HealthcareSolutions #Generics

Aveva Drug Delivery Systems enhances portfolio with generic Fentanyl TDS launch! February 17, 2025 – 𝙈𝙞𝙧𝙖𝙢𝙖𝙧, 𝙁𝙇 We are excited to announce that Aveva Drug Delivery Systems, a DifGen Pharmaceuticals company, has successfully launched its generic Fentanyl Transdermal System (TDS)—marking its third complex transdermal drug launch in just 15 months. This achievement underscores our commitment to advancing transdermal drug delivery and expanding access to high-quality, cost-effective treatments for patients in need. Read more about this milestone here: https://lnkd.in/d4g3gBbn 

Today, on World Cancer Day, we come together to honor those battling cancer, celebrate survivors, and remember those we have lost. This global movement serves as a powerful reminder of our shared commitment to increasing awareness, advancing prevention, and improving treatment for all.   Together, we can make a difference. Let’s honor this day by spreading awareness, supporting research, and offering hope to those who need it most

We are thrilled to announce that Mr. Sukhad Juneja has joined us as Chief Scientific and Commercial Officer. Sukhad is a seasoned pharmaceutical industry veteran with close to two decades of leadership experience managing Scientific Affairs, Project and Alliance Management, Business Development, Portfolio Management and Intellectual Property Affairs, Product launches, Commercial Operations and International market expansion. In his role at DifGen, Sukhad will be responsible for driving forward our R&D activities, bolstering our pipeline as we continue to embark on our journey of developing high barrier to entry complex drug products, enhancing our R&D Alliance Management and commercial product launch processes as well as leading our commercial expansion into international markets. "Since inception DifGen has shown remarkable ability to deliver on differentiated products and create exceptional value for all stakeholders, that’s exactly the environment I want to be part of. I am excited to be a core member of the DifGen team and collaborate with the talented team here to build a world class organisation." said Sukhad Juneja upon joining. Founder and Co-CEO Ramandeep Singh Jaj shared his thoughts : "We are thrilled to welcome Sukhad to our leadership team. His expertise and proven ability to drive specific outcomes align perfectly with our company's mission and strategic goals. We are confident that Sukhad's leadership will propel us towards new opportunities and greater success." Founder and Co-CEO Santhanakrishnan Srinivasan Ph.D, MBA added : "As we continue to drive DifGen's strategic goals Sukhad will play a key role in shaping strategy, driving innovation and expanding market presence. His vision and expertise will be invaluable as we move forward." DifGen remains committed to its mission of innovation and operational excellence and this appointment underscores our dedication to building a strong leadership team that drives innovation and growth.

This Christmas, we at DifGen Pharmaceuticals are grateful for the trust and partnerships that have shaped this incredible year. Let's celebrate the joy, warmth, and togetherness that the holidays bring. Wishing you and your loved ones a season filled with peace, good health and happiness. Here's to wrapping up the year with gratitude and wishing everyone a Merry Christmas and a Happy New Year on behalf of our entire DifGen family!

Festivities in full swing with the DifGen Pharmaceuticals India team as they celebrate Diwali and Dusshera, honoring traditions and sharing great moments. Grateful for the camaraderie and the memories!

DifGen Pharmaceuticals LLC, a U.S.-based Global Pharmaceutical company, with a primary focus on developing and manufacturing complex, high-barrier-to-entry generics and specialty pharmaceutical products, today announced the appointment of Roberta Loomar as its Global General Counsel, effective November 1, 2024.   In a joint statement, Ramandeep Singh Jaj and Dr. Santhanakrishnan Srinivasan Ph.D, MBA, Founders and Co-CEOs stated, “Roberta is an outstanding leader who brings a wealth of pharmaceutical expertise to her new role as Global General Counsel. We are excited to have her join our executive team to help grow DifGen into becoming a market leader in our space.”   Ms. Loomar has almost 25 years of diverse and extensive experience in the pharmaceutical industry as a legal and compliance professional. She previously worked at Apotex Corp for almost 10 years as their SVP, General Counsel - US and LATAM.  Prior to joining Apotex Corp, she worked at Watson Pharmaceuticals and Andrx Pharmaceuticals, respectively, as their Assistant General Counsel and at various times, leading their compliance functions.  Before moving in-house, Ms. Loomar was a trial lawyer for various firms including Hogan & Hartson and Hughes Hubbard & Reed. Ms. Loomar earned her J.D. from the University of Miami School of Law and holds a B.S. degree in telecommunications from the University of Florida.    Ms. Loomar stated, “I am thrilled to join DifGen Pharmaceuticals and together with DifGen’s talented team, I am certain that we will grow the Company’s position as a leader in the generics and specialty pharmaceutical sectors. I look forward to working closely with the entire DifGen team to help increase accessibility to high quality medication”. 

Walk-In Drive - 19th October 2024   DifGen India Pharmaceuticals Pvt Ltd

And that's a wrap on CPHI Milan 2024! 🎉 It’s been an incredible few days of innovation, meaningful conversations, and new connections. We had the pleasure of meeting so many industry leaders, sharing insights, and exploring the future of pharmaceuticals together. From discussing breakthrough solutions to exchanging ideas at Booth #14B20, every moment was a reminder of why we love what we do. 💡 A huge thank you to everyone who stopped by and made this event unforgettable. We can’t wait to see you all again next year! Let’s keep pushing the boundaries of what’s possible. See you in 2025! 🚀 #CPHI2024